Related references
Note: Only part of the references are listed.Oral delivery of the anti-tumor necrosis factor α domain antibody, V565, results in high intestinal and fecal concentrations with minimal systemic exposure in cynomolgus monkeys
J. Scott Crowe et al.
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY (2019)
In situ immune response and mechanisms of cell damage in central nervous system of fatal cases microcephaly by Zika virus
Raimunda S. S. Azevedo et al.
SCIENTIFIC REPORTS (2018)
Tissue Drug Concentrations of Anti-tumor Necrosis Factor Agents Are Associated with the Long-term Outcome of Patients with Crohn's Disease
Takeo Yoshihara et al.
INFLAMMATORY BOWEL DISEASES (2017)
Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease
Magali Lemaitre et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
The association of tissue anti-TNF drug levels with serological and endoscopic disease activity in inflammatory bowel disease: the ATLAS study
Andres J. Yarur et al.
GUT (2016)
Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases
Bella Ungar et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis
Stefanos Bonovas et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2016)
Effects of AVX-470, an Oral, Locally Acting Anti-Tumour Necrosis Factor Antibody, on Tissue Biomarkers in Patients with Active Ulcerative Colitis
Deborah S. Hartman et al.
JOURNAL OF CROHNS & COLITIS (2016)
AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial
M. Scott Harris et al.
JOURNAL OF CROHNS & COLITIS (2016)
Molecular mechanism of action of anti-tumor necrosis factor antibodies in inflammatory bowel diseases
Ulrike Billmeier et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis
Johannan F. Brandse et al.
GASTROENTEROLOGY (2015)
Proteolytic Cleavage and Loss of Function of Biologic Agents That Neutralize Tumor Necrosis Factor in the Mucosa of Patients With Inflammatory Bowel Disease
Paolo Biancheri et al.
GASTROENTEROLOGY (2015)
From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease
Charles W. Randall et al.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY (2015)
A CD3-Specific Antibody Reduces Cytokine Production and Alters Phosphoprotein Profiles in Intestinal Tissues From Patients With Inflammatory Bowel Disease
Anna Vossenkaemper et al.
GASTROENTEROLOGY (2014)
Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease
Ole Haagen Nielsen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Share Paper
